Aquaporin 9, a promising predictor for the cytocidal effects of arsenic trioxide in acute promyelocytic leukemia cell lines and primary blasts

Iriyama,Noriyoshi; Yuan,Bo; Yoshino,Yuta; Hatta,Yoshihiro; Horikoshi,Akira; Aizawa,Shin; Takeuchi,Jin; Toyoda,Hiroo

doi:10.3892/or.2013.2388

Aquaporin 9, a promising predictor for the cytocidal effects of arsenic trioxide in acute promyelocytic leukemia cell lines and primary blasts

Authors:
- Noriyoshi Iriyama
- Bo Yuan
- Yuta Yoshino
- Yoshihiro Hatta
- Akira Horikoshi
- Shin Aizawa
- Jin Takeuchi
- Hiroo Toyoda
View Affiliations

Affiliations: Department of Hematology and Rheumatology, Nihon University School of Medicine, Itabashi Hospital, Itabashi-ku, Tokyo 173-8610, Japan, Department of Clinical Molecular Genetics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 192-0392, Japan, Department of Functional Morphology, Nihon University School of Medicine, Itabashi Hospital, Itabashi-ku, Tokyo 173-8610, Japan
Published online on: April 5, 2013 https://doi.org/10.3892/or.2013.2388
Pages: 2362-2368

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A close correlation between the cytocidal effects of arsenic trioxide (ATO) and aquaporin-9 (AQP9) expression levels has been proposed, yet detailed studies are still needed to confirm this association. Thus, in the present study, the correlation between the expression levels of AQP9 and sensitivity to ATO was investigated using two acute promyelocytic leukemia (APL) cell lines, NB4 and HT93A, as well as primary APL cells from newly diagnosed and relapsed APL patients. A substantially higher sensitivity to ATO-mediated induction of apoptosis was observed in the NB4 cells when compared to that in the HT93A cells. In addition, markedly higher expression levels of AQP9, as assessed using flow cytometry, along with more intracellular arsenic accumulation, were observed in the NB4 cells. More importantly, similar to APL cell lines, the trend of expression levels of AQP9 correlated closely with the differential sensitivity to ATO-mediated induction of apoptosis in primary APL cells. In contrast, no correlation was observed between ATO sensitivity associated with AQP9 expression levels and the expression profiles of cell surface markers as well as chromosomal alterations. These results provide direct evidence that the expression levels of AQP9, rather than other biomarkers such as cell surface markers and chromosomal alterations, correlate closely with the sensitivity to ATO in both APL cell lines and primary blasts. These findings suggest that the AQP9 expression status of APL patients is a predictive marker for the successful outcome of ATO treatment, since AQP9 plays a pivotal role in various arsenite-mediated biological effects on normal and cancer cells. Moreover, flow cytometry may be a new convenient and valuable tool for analyzing the AQP9 status of APL patients compared to current methods such as western blotting.

View Figures

View References

1	de Thé H, Chomienne C, Lanotte M, Degos L and Dejean A: The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature. 347:558–561. 1990.PubMed/NCBI
2	Goddard AD, Borrow J, Freemont PS and Solomon E: Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science. 254:1371–1374. 1991. View Article : Google Scholar : PubMed/NCBI
3	Tong JH, Dong S, Geng JP, Huang W, Wang ZY, Sun GL, Chen SJ, Chen Z, Larsen CJ and Berger R: Molecular rearrangements of the MYL gene in acute promyelocytic leukemia (APL, M3) define a breakpoint cluster region as well as some molecular variants. Oncogene. 7:311–316. 1992.PubMed/NCBI
4	Burnett AK, Grimwade D, Solomon E, Wheatley K and Goldstone AH: Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood. 93:4131–4143. 1999.PubMed/NCBI
5	Melnick A and Licht JD: Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 93:3167–3215. 1999.PubMed/NCBI
6	Cohen MH, Hirschfeld S, Flamm Honig S, Ibrahim A, Johnson JR, O'Leary JJ, White RM, Williams GA and Pazdur R: Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist. 6:4–11. 2001. View Article : Google Scholar : PubMed/NCBI
7	Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z and Wang ZY: Use of arsenic trioxide (As₂O₃) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 89:3354–3360. 1997.PubMed/NCBI
8	Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP and Warrell RP Jr: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 339:1341–1348. 1998. View Article : Google Scholar : PubMed/NCBI
9	Dilda PJ and Hogg PJ: Arsenical-based cancer drugs. Cancer Treat Rev. 33:542–564. 2007. View Article : Google Scholar
10	Litzow MR: Arsenic trioxide. Expert Opin Pharmacother. 9:1773–1785. 2008. View Article : Google Scholar
11	Fujisawa S, Ohno R, Shigeno K, Sahara N, Nakamura S, Naito K, Kobayashi M, Shinjo K, Takeshita A, Suzuki Y, Hashimoto H, Kinoshita K, Shimoya M, Kaise T and Ohnishi K: Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide. Cancer Chemother Pharmacol. 59:485–493. 2007. View Article : Google Scholar : PubMed/NCBI
12	Iriyama N, Yoshino Y, Yuan B, Horikoshi A, Hirabayashi Y, Hatta Y, Toyoda H and Takeuchi J: Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient. J Hematol Oncol. 5:1–11. 2012. View Article : Google Scholar : PubMed/NCBI
13	Kiguchi T, Yoshino Y, Yuan B, Yoshizawa S, Kitahara T, Akahane D, Gotoh M, Kaise T, Toyoda H and Ohyashiki K: Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia. Leuk Res. 34:403–405. 2010. View Article : Google Scholar : PubMed/NCBI
14	Yoshino Y, Yuan B, Miyashita SI, Iriyama N, Horikoshi A, Shikino O, Toyoda H and Kaise T: Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia. Anal Bioanal Chem. 393:689–697. 2009. View Article : Google Scholar : PubMed/NCBI
15	Yuan B, Yoshino Y, Kaise T and Toyoda H: Application of arsenic trioxide therapy for patients with leukaemia. Biological Chemistry of As, Sb and Bi. Sun HZ: John Wiley and Sons, Ltd; New York: pp. 263–292. 2011
16	Bhattacharjee H, Carbrey J, Rosen BP and Mukhopadhyay R: Drug uptake and pharmacological modulation of drug sensitivity in leukemia by AQP9. Biochem Biophys Res Commun. 322:836–841. 2004. View Article : Google Scholar : PubMed/NCBI
17	Lee TC, Ho IC, Lu WJ and Huang JD: Enhanced expression of multidrug resistance-associated protein 2 and reduced expression of aquaglyceroporin 3 in an arsenic-resistant human cell line. J Biol Chem. 281:18401–18407. 2006. View Article : Google Scholar : PubMed/NCBI
18	Leung J, Pang A, Yuen WH, Kwong YL and Tse EW: Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood. 109:740–746. 2007. View Article : Google Scholar : PubMed/NCBI
19	Liu Z, Shen J, Carbrey JM, Mukhopadhyay R, Agre P and Rosen BP: Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9. Proc Natl Acad Sci USA. 99:6053–6058. 2002. View Article : Google Scholar : PubMed/NCBI
20	Yoshino Y, Yuan B, Kaise T, Takeichi M, Tanaka S, Hirano T, Kroetz DL and Toyoda H: Contribution of aquaporin 9 and multidrug resistance-associated protein 2 to differential sensitivity to arsenite between primary cultured chorion and amnion cells prepared from human fetal membranes. Toxicol Appl Pharmacol. 257:198–208. 2011. View Article : Google Scholar
21	Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, Li JM, Tang W, Zhao WL, Wu W, Sun HP, Chen QS, Chen B, Zhou GB, Zelent A, Waxman S, Wang ZY, Chen SJ and Chen Z: Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 106:3342–3347. 2009.PubMed/NCBI
22	Yuan B, Ohyama K, Bessho T and Toyoda H: Contribution of inducible nitric oxide synthase and cyclooxygenase-2 to apoptosis induction in smooth chorion trophoblast cells of human fetal membrane tissues. Biochem Biophys Res Commun. 341:822–827. 2006. View Article : Google Scholar : PubMed/NCBI
23	Yuan B, Ohyama K, Bessho T, Uchide N and Toyoda H: Imbalance between ROS production and elimination results in apoptosis induction in primary smooth chorion trophoblast cells prepared from human fetal membrane tissues. Life Sci. 82:623–630. 2008. View Article : Google Scholar
24	Yuan B, Ohyama K, Takeichi M and Toyoda H: Direct contribution of inducible nitric oxide synthase expression to apoptosis induction in primary smooth chorion trophoblast cells of human fetal membrane tissues. Int J Biochem Cell Biol. 41:1062–1069. 2009. View Article : Google Scholar
25	Wang ZY and Chen Z: Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 111:2505–2515. 2008. View Article : Google Scholar : PubMed/NCBI
26	Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Niu C, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang ZY, de The H, Chen SJ and Chen Z: Use of arsenic trioxide (As₂O₃) in the treatment of acute promyelocytic leukemia (APL): I. As₂O₃ exerts dose-dependent dual effects on APL cells. Blood. 89:3345–3353. 1997.PubMed/NCBI
27	Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ and Chen Z: Arsenic trioxide, a therapeutic agent for APL. Oncogene. 20:7146–7153. 2001. View Article : Google Scholar : PubMed/NCBI
28	Di Bona E, Sartori R, Zambello R, Guercini N, Madeo D and Rodeghiero F: Prognostic significance of CD56 antigen expression in acute myeloid leukemia. Haematologica. 87:250–256. 2002.
29	Ferrara F, Morabito F, Martino B, Specchia G, Liso V, Nobile F, Boccuni P, Di Noto R, Pane F, Annunziata M, Schiavone EM, De Simone M, Guglielmi C, Del Vecchio L and Lo Coco F: CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol. 18:1295–1300. 2000.PubMed/NCBI
30	Montesinos P, Rayon C, Vellenga E, Brunet S, Gonzalez J, Gonzalez M, Holowiecka A, Esteve J, Bergua J, Gonzalez JD, Rivas C, Tormo M, Rubio V, Bueno J, Manso F, Milone G, de la Serna J, Perez I, Perez-Encinas M, Krsnik I, Ribera JM, Escoda L, Lowenberg B and Sanz MA: Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood. 117:1799–1805. 2011. View Article : Google Scholar
31	Schwarzinger I, Valent P, Koller U, Marosi C, Schneider B, Haas O, Knapp W, Lechner K and Bettelheim P: Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia. J Clin Oncol. 8:423–430. 1990.PubMed/NCBI
32	Vahdat L, Maslak P, Miller WH Jr, Eardley A, Heller G, Scheinberg DA and Warrell RP Jr: Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood. 84:3843–3849. 1994.PubMed/NCBI
33	Andus T, Targan SR, Deem R and Toyoda H: Measurement of tumor necrosis factor alpha mRNA in small numbers of cells by quantitative polymerase chain reaction. Reg Immunol. 5:11–17. 1993.PubMed/NCBI
34	Ruan XZ, Varghese Z, Powis SH and Moorhead JF: Human mesangial cells express inducible macrophage scavenger receptor. Kidney Int. 56:440–451. 1999. View Article : Google Scholar : PubMed/NCBI
35	Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, Huang Y, Zhang JW, Xiong SM, Chen SJ, Wang ZY, Chen Z and Chen GQ: Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia. 14:262–270. 2000. View Article : Google Scholar
36	Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY and Chen Z: In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As₂O₃) in the treatment of acute promyelocytic leukemia: As₂O₃ induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 88:1052–1061. 1996.PubMed/NCBI
37	Iriyama N, Yuan B, Hatta Y, Horikoshi A, Yoshino Y, Toyoda H, Aizawa S and Takeuchi J: Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A. Oncol Rep. 28:1875–1882. 2012.PubMed/NCBI